Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Bioton S.A. is a biotechnology company based in Poland, specializing in the production of biopharmaceuticals, particularly insulin and other diabetes-related products. Its competitive position is bolstered by a strong presence in the European market and a focus on high-quality, affordable biosimilars, which are critical in addressing the growing diabetes epidemic.
Bioton generates revenue primarily through the sale of insulin and biosimilars, leveraging its cost-effective production capabilities and established distribution networks in Europe. The company's competitive advantage lies in its proprietary manufacturing processes that reduce costs while maintaining high quality, allowing for competitive pricing in a price-sensitive market.
Regulatory approvals for new insulin formulations and biosimilars
Market penetration in emerging European markets
Partnerships or collaborations with larger pharmaceutical companies
Changes in diabetes prevalence rates in Europe
Regulatory changes in the pharmaceutical industry that could impact product approvals
Technological disruption in biopharmaceutical manufacturing processes
Emergence of new competitors in the biosimilar space
Pricing pressures from larger pharmaceutical companies
Low return on equity (0.7%) may indicate inefficiencies in capital utilization
Limited cash flow generation could restrict growth opportunities
moderate - The demand for biopharmaceuticals is somewhat insulated from economic cycles, but overall healthcare spending can be influenced by GDP growth.
Interest rates impact Bioton primarily through financing costs for any potential expansion or R&D investments. Higher rates could increase borrowing costs, affecting profitability and valuation multiples.
minimal - Bioton has a low debt/equity ratio of 0.10, indicating limited reliance on external credit.
growth - Investors are likely attracted to Bioton for its high revenue growth rate and potential in the expanding diabetes market.
moderate - The stock has shown some volatility with a 1-year return of -4.3%, indicating sensitivity to market conditions and company-specific news.
